Although it is well established that in primary PC there is heterogeneity in terms of ERG rearrangement, data is limited on ERG heterogeneity within a metastatic patient or potential changes in the ETS rearrangement event over the course of therapy, similar to HER-2 gene amplification that is enhanced as breast cancer progresses [50]. The gene discussed is ERG; the disease is pachyonychia congenita.